HC Wainwright Reaffirms “Buy” Rating for Lisata Therapeutics (NASDAQ:LSTA)

HC Wainwright reiterated their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA) in a report released on Friday morning, Benzinga reports. They currently have a $15.00 target price on the stock.

Lisata Therapeutics Stock Performance

Shares of NASDAQ:LSTA opened at $3.55 on Friday. The business has a fifty day moving average of $3.29 and a 200-day moving average of $3.06. Lisata Therapeutics has a twelve month low of $1.95 and a twelve month high of $3.83. The firm has a market cap of $29.49 million, a PE ratio of -1.44 and a beta of 1.24.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.08. On average, analysts anticipate that Lisata Therapeutics will post -3.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. BML Capital Management LLC increased its position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 10.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 269,839 shares of the company’s stock after purchasing an additional 26,000 shares during the quarter. Lisata Therapeutics makes up 0.6% of BML Capital Management LLC’s portfolio, making the stock its 24th biggest position. BML Capital Management LLC owned 3.31% of Lisata Therapeutics worth $737,000 at the end of the most recent reporting period. Institutional investors own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.